Condition: Hospital-acquired Bacterial Pneumonia (HABP) · Ventilator-associated Bacterial Pneumonia (VABP) · Complicated Intra-abdominal Infection (cIAI) · Sponsor: Qilu Pharmaceutical Co., Ltd.
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Infections evaluated in the study will be hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), and Bloodstream Infection (BSI).
This description comes directly from the study's public registry record.
Haihui Huang, PhD · 021-52888195 · Huanghaihui73@aliyun.com
Always discuss trial participation with your own doctor first.
| Huashan Hospital, Fudan Universit | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07089186